CVRX Stock Price, CVRx, Inc. Quote, Chart

Market Summary

USD14.69+0.30

Market Closed

2.08%

CVRX Stock Price

View Fullscreen

CVRX RSI Chart

CVRX Valuation

Market Cap

307.4M

Price/Earnings (Trailing)

-7.46

Price/Sales (Trailing)

7.82

EV/EBITDA

-6.35

Price/Free Cashflow

-7.76

CVRX Price/Sales (Trailing)

CVRX Profitability

Operating Margin

84.08%

EBT Margin

-104.47%

Return on Equity

-54.25%

Return on Assets

-35.75%

Free Cashflow Yield

-12.88%

CVRX Fundamentals

CVRX Revenue

Revenue (TTM)

39.3M

Rev. Growth (Yr)

57.54%

Rev. Growth (Qtr)

7.55%

CVRX Earnings

Earnings (TTM)

-41.2M

Earnings Growth (Yr)

13.03%

Earnings Growth (Qtr)

-1.69%

Breaking Down CVRX Revenue

Last 7 days

-1.4%

Last 30 days

-18.3%

Last 90 days

-46.1%

Trailing 12 Months

55.0%

How does CVRX drawdown profile look like?

CVRX Financial Health

Current Ratio

14.25

Debt/Equity

0.38

Debt/Cashflow

-1.34

CVRX Investor Care

Shares Dilution (1Y)

1.15%

Diluted EPS (TTM)

-1.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	26.4M	30.8M	35.2M	39.3M
2022	14.3M	16.2M	19.0M	22.5M
2021	7.8M	9.5M	11.3M	13.0M
2020	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CVRx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	palmer craig e.	acquired	221	0.237	934	svp, u.s. sales
Feb 29, 2024	johnson & johnson	acquired	2,792	0.724307	3,855	-
Feb 23, 2024	verrastro paul	gifted	-	-	-1,650	chief mktg & strat officer
Feb 20, 2024	verrastro paul	acquired	25,705	5.141	5,000	chief mktg & strat officer
Feb 20, 2024	verrastro paul	sold	-55,748	21.905	-2,545	chief mktg & strat officer
Feb 16, 2024	johnson & johnson	sold	-96,142	25.81	-3,725	-
Feb 16, 2024	johnson & johnson	acquired	96,020	0.158	607,725	-
Jan 29, 2024	yared nadim	acquired	1,422	0.237	6,000	chief executive officer
Dec 28, 2023	slattery joseph p	acquired	984	0.50472	1,950	-
Dec 14, 2023	behbahani ali	acquired	74.892	0.237	316	-

Which funds bought or sold CVRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-72.67	-250,000	46,000	-%
Apr 25, 2024	Valeo Financial Advisors, LLC	new	-	273,600	273,600	0.01%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-24.5	-666,712	518,074	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-74.95	-40,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	102,322	197,726	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-25,368	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	200	200	-%
Apr 11, 2024	GSG Advisors LLC	reduced	-78.19	-4,139,100	603,854	0.22%
Apr 05, 2024	GAMMA Investing LLC	new	-	310	310	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.28	9,343,970	17,687,900	-%

Are Funds Buying or Selling CVRX?

Are funds buying CVRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CVRX

No. of Funds

Unveiling CVRx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	vensana capital i gp, llc	8.2%	1,711,355	SC 13G/A
Feb 02, 2024	johnson & johnson	19.2%	4,109,336	SC 13G/A
Jan 19, 2024	cooperatieve gilde healthcare iv u.a.	6.6%	1,368,206	SC 13D/A
Dec 29, 2023	cooperatieve gilde healthcare iv u.a.	7.7%	1,598,763	SC 13D/A
Feb 14, 2023	soleus capital master fund, l.p.	4.9%	1,014,640	SC 13G/A
Feb 06, 2023	gsk plc	4.9%	1,007,583	SC 13G
Feb 03, 2023	vensana capital i gp, llc	8.3%	1,711,355	SC 13G/A
Apr 29, 2022	soleus capital master fund, l.p.	5.1%	1,044,040	SC 13G
Feb 10, 2022	vensana capital i gp, llc	7.2%	1,461,831	SC 13G
Feb 07, 2022	johnson & johnson	19.6%	4,109,573	SC 13G

Recent SEC filings of CVRx, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 11, 2024	PRE 14A	PRE 14A
Mar 27, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 20, 2024	144	Notice of Insider Sale Intent
Feb 14, 2024	4	Insider Trading
Feb 09, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to CVRx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

CVRx, Inc. News

Latest updates

CVRx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	7.6%	11,305,000	10,511,000	9,500,000	7,979,000	7,176,000	6,186,000	5,031,000	4,076,000	3,658,000	3,395,000	3,123,000	2,860,000	1,928,500	997,000	1,250,000
Cost Of Revenue	1.7%	1,720,000	1,691,000	1,517,000	1,328,000	1,509,000	1,340,000	1,201,000	949,000	984,000	876,000	913,000	867,000	-	212,000	345,000
Gross Profit	8.7%	9,585,000	8,820,000	7,983,000	6,651,000	5,667,000	4,846,000	3,830,000	3,127,000	2,674,000	2,519,000	2,210,000	1,993,000	-	785,000	905,000
Operating Expenses	4.9%	19,246,000	18,348,000	19,735,000	18,813,000	17,146,000	14,972,000	14,844,000	13,035,000	11,462,000	9,810,000	7,882,000	6,210,000	-	3,827,000	3,965,000
S&GA Expenses	8.6%	17,005,000	15,652,000	16,455,000	15,397,000	14,100,000	12,679,000	12,489,000	10,777,000	9,665,000	8,111,000	5,627,000	4,460,000	-	2,327,000	1,834,000
R&D Expenses	-16.9%	2,241,000	2,696,000	3,280,000	3,416,000	3,046,000	2,293,000	2,355,000	2,258,000	1,797,000	1,699,000	2,255,000	1,750,000	-	1,500,000	2,131,000
EBITDA Margin	14.5%	-0.99	-1.15	-1.36	-1.59	-1.81	-2.14	-2.25	-2.98	-3.11	-1.02	-1.20	-1.47	-1.90	-	-
Interest Expenses	16.0%	579,000	499,000	481,000	240,000	165,000	-	-	-	396,000	614,000	608,000	601,000	-	621,000	618,000
Income Taxes	-2.5%	39,000	40,000	34,000	34,000	28,000	32,000	23,000	26,000	25,000	23,000	26,000	17,000	-	19,000	22,000
Earnings Before Taxes	-1.7%	-9,124,000	-8,971,000	-11,617,000	-11,340,000	-10,508,000	-9,798,000	-11,048,000	-9,965,000	-10,545,000	-6,110,000	-17,722,000	-8,610,000	-	-3,208,000	-3,645,000
EBT Margin	13.4%	-1.04	-1.21	-1.40	-1.62	-1.84	-2.18	-2.33	-3.11	-3.30	-1.24	-1.47	-1.80	-2.32	-	-
Net Income	-1.7%	-9,163,000	-9,011,000	-11,651,000	-11,374,000	-10,536,000	-9,830,000	-11,071,000	-9,991,000	-10,570,000	-6,133,000	-17,748,000	-8,627,000	-	-3,227,000	-3,667,000
Net Income Margin	13.4%	-1.05	-1.21	-1.41	-1.62	-1.84	-2.19	-2.34	-3.12	-3.30	-1.25	-1.48	-1.81	-2.33	-	-
Free Cashflow	1.9%	-8,008,000	-8,164,000	-12,951,000	-10,489,000	-10,920,000	-11,360,000	-10,145,000	-10,937,000	-7,553,000	-9,380,000	-6,843,000	-5,139,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	8.3%	115	106	115	123	125	127	134	144	153	182	55.00	65.00
Current Assets	8.2%	112	104	112	121	123	124	132	142	151	181	54.00	64.00
Cash Equivalents	9.1%	91.00	83.00	91.00	103	106	110	121	131	142	171	47.00	59.00
Inventory	0.9%	11.00	11.00	11.00	8.00	7.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00
Net PPE	2.3%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	0.00
Liabilities	66.6%	39.00	24.00	25.00	23.00	16.00	8.00	7.00	8.00	7.00	26.00	44.00	28.00
Current Liabilities	6.2%	8.00	7.00	9.00	8.00	8.00	7.00	6.00	7.00	6.00	9.00	25.00	8.00
Long Term Debt	104.4%	29.00	14.00	14.00	14.00	7.00	-	-	-	-	16.00	18.00	19.00
LT Debt, Non Current	104.4%	29.00	14.00	14.00	14.00	7.00	-	-	-	-	16.00	18.00	19.00
Shareholder's Equity	-8.3%	76.00	83.00	90.00	100	109	118	127	137	146	156	-	-
Retained Earnings	-2.0%	-477	-468	-459	-447	-436	-425	-415	-404	-394	-384	-378	-351
Additional Paid-In Capital	0.4%	553	551	549	547	545	544	543	542	541	540	59.00	59.00
Shares Outstanding	0.3%	21.00	21.00	21.00	21.00	21.00	21.00	20.00	20.00	20.00	20.00	-	0.00
Float	-	-	-	190	-	-	-	72.00	-	-	-	10.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	3.5%	-7,839	-8,125	-12,808	-10,249	-10,841	-11,096	-10,096	-10,644	-7,015	-9,215	-6,464	-5,038	-	-	-
Share Based Compensation	3.8%	1,590	1,532	1,476	1,705	1,065	929	1,100	793	753	474	624	61.00	-	-	-
Cashflow From Investing	-333.3%	-169	-39.00	-143	-240	-79.00	-264	-49.00	-293	-538	-165	-379	-101	-	-	-
Cashflow From Financing	4192.0%	15,580	363	473	7,568	7,117	7.00	321	48.00	-21,287	133,168	-	2.00	-	-	-

CVRX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Revenue	$ 39,295	$ 22,469
Cost of goods sold	6,256	4,999
Gross profit	33,039	17,470
Operating expenses:
Research and development	11,633	9,952
Selling, general and administrative	64,509	50,045
Total operating expenses	76,142	59,997
Loss from operations	(43,103)	(42,527)
Interest expense	(1,799)	(165)
Other income, net	3,850	1,373
Loss before income taxes	(41,052)	(41,319)
Provision for income taxes	(147)	(109)
Net loss	(41,199)	(41,428)
Cumulative translation adjustment		(9)
Comprehensive loss	$ (41,199)	$ (41,437)
Net loss per share, basic	$ (1.99)	$ (2.02)
Net loss per share, diluted	$ (1.99)	$ (2.02)
Weighted-average common shares used to compute net loss per share, basic	20,754,375	20,532,838
Weighted-average common shares used to compute net loss per share, diluted	20,754,375	20,532,838

CVRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 90,569	$ 106,194
Accounts receivable, net of allowances of $508 and $679, respectively	7,551	5,504
Inventory	10,983	6,957
Prepaid expenses and other current assets	2,987	4,223
Total current assets	112,090	122,878
Property and equipment, net	1,763	1,698
Operating lease right-of-use asset	1,349	334
Other non-current assets	27	27
Total assets	115,229	124,937
Current liabilities:
Accounts payable	1,884	1,719
Accrued expenses	5,980	6,369
Total current liabilities	7,864	8,088
Long-term debt	29,222	6,747
Operating lease liability, non-current portion	1,160	117
Other long-term liabilities	1,036	805
Total liabilities	39,282	15,757
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2023 and 2022; 20,879,199 and 20,663,736 shares issued and outstanding as of December 31, 2023 and 2022, respectively, respectively	209	207
Additional paid-in capital	553,326	545,362
Accumulated deficit	(477,381)	(436,182)
Accumulated other comprehensive loss	(207)	(207)
Total stockholders' equity	75,947	109,180
Total liabilities and stockholders' equity	$ 115,229	$ 124,937

About CVRx, Inc.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Nadim Yared
WEBSITE	cvrx.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	160

CVRx, Inc. Frequently Asked Questions

What is the ticker symbol for CVRx, Inc.? What does CVRX stand for in stocks?

CVRX is the stock ticker symbol of CVRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CVRx, Inc. (CVRX)?

As of Fri Apr 26 2024, market cap of CVRx, Inc. is 307.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CVRX stock?

You can check CVRX's fair value in chart for subscribers.

What is the fair value of CVRX stock?

You can check CVRX's fair value in chart for subscribers. The fair value of CVRx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CVRx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CVRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CVRx, Inc. a good stock to buy?

The fair value guage provides a quick view whether CVRX is over valued or under valued. Whether CVRx, Inc. is cheap or expensive depends on the assumptions which impact CVRx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CVRX.

What is CVRx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CVRX's PE ratio (Price to Earnings) is -7.46 and Price to Sales (PS) ratio is 7.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVRX PE ratio will change depending on the future growth rate expectations of investors.